HOOKIPA Pharma Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 81.58 million compared to USD 64.92 million a year ago. Basic loss per share from continuing operations was USD 0.86 compared to USD 0.99 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8933 USD | +10.82% | +21.87% | +10.28% |
Apr. 25 | Transcript : HOOKIPA Pharma Inc. - Special Call | |
Apr. 25 | HOOKIPA Pharma Inc. Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.28% | 88.39M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- HOOK Stock
- News HOOKIPA Pharma Inc.
- HOOKIPA Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023